Oscillatory positive expiratory pressure therapy in COPD (O-COPD) : a randomised controlled trial
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Oscillatory positive expiratory pressure (OPEP) devices are intended to facilitate sputum clearance and reduce cough, but there is limited evidence for their effectiveness in COPD, or to guide patient selection. We aimed to assess the impact of OPEP therapy on quality of life and objective measures of cough and sleep disturbance in patients with COPD with regular sputum production.
METHODS: We enrolled stable patients with COPD, who reported sputum production every day or most days, into an assessor-blind, parallel-group, randomised controlled trial comparing 3 months of using an Acapella device against usual care (including use of the active cycle of breathing technique). The primary outcome was cough-related quality of life measured using the Leicester Cough Questionnaire (LCQ). Secondary outcomes included fatigue (Functional Assessment of Chronic Illness Therapy, FACIT score) and generic quality of life (EuroQol-5 Dimensions, EQ-5D). In a substudy (n=45), objective monitoring of cough and disturbance/movement during sleep were also available.
RESULTS: 122 participants (61/61 OPEP/control) were recruited, 40% female, 17% smokers, FEV1 38 (25-56)% predicted, and age 62±10 years. 103 completed the study (55/48 OPEP/control). Use of OPEP was associated with an improvement in LCQ compared with controls; MD (95% CI) 1.03 (0.71 to 2.10); (p=0.03), FACIT score 4.68 (1.34 to 8.02); (p<0.001) and EQ-5D 4.00 (0.49 to 19.75); (p=0.04). There was also an improvement in cough frequency -60 (-43 to -95) coughs/24 hours (p<0.001), but no statistically significant effect on sleep disturbance was identified.
CONCLUSIONS: Regular use of an Acapella device improves symptoms and quality of life in people with COPD who produce sputum daily or most days.
TRIAL REGISTRATION NUMBER: ISRCTN44651852.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Thorax - 78(2023), 2 vom: 24. Feb., Seite 136-143 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alghamdi, Saeed M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COPD Exacerbations |
|---|
| Anmerkungen: |
Date Completed 16.01.2023 Date Revised 18.04.2023 published: Print-Electronic ISRCTN: ISRCTN44651852 CommentIn: Thorax. 2023 Feb;78(2):113-115. - PMID 36167723 Citation Status MEDLINE |
|---|
| doi: |
10.1136/thorax-2022-219077 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344677761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344677761 | ||
| 003 | DE-627 | ||
| 005 | 20231226023329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/thorax-2022-219077 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344677761 | ||
| 035 | |a (NLM)35948418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alghamdi, Saeed M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oscillatory positive expiratory pressure therapy in COPD (O-COPD) |b a randomised controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2023 | ||
| 500 | |a Date Revised 18.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ISRCTN: ISRCTN44651852 | ||
| 500 | |a CommentIn: Thorax. 2023 Feb;78(2):113-115. - PMID 36167723 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Oscillatory positive expiratory pressure (OPEP) devices are intended to facilitate sputum clearance and reduce cough, but there is limited evidence for their effectiveness in COPD, or to guide patient selection. We aimed to assess the impact of OPEP therapy on quality of life and objective measures of cough and sleep disturbance in patients with COPD with regular sputum production | ||
| 520 | |a METHODS: We enrolled stable patients with COPD, who reported sputum production every day or most days, into an assessor-blind, parallel-group, randomised controlled trial comparing 3 months of using an Acapella device against usual care (including use of the active cycle of breathing technique). The primary outcome was cough-related quality of life measured using the Leicester Cough Questionnaire (LCQ). Secondary outcomes included fatigue (Functional Assessment of Chronic Illness Therapy, FACIT score) and generic quality of life (EuroQol-5 Dimensions, EQ-5D). In a substudy (n=45), objective monitoring of cough and disturbance/movement during sleep were also available | ||
| 520 | |a RESULTS: 122 participants (61/61 OPEP/control) were recruited, 40% female, 17% smokers, FEV1 38 (25-56)% predicted, and age 62±10 years. 103 completed the study (55/48 OPEP/control). Use of OPEP was associated with an improvement in LCQ compared with controls; MD (95% CI) 1.03 (0.71 to 2.10); (p=0.03), FACIT score 4.68 (1.34 to 8.02); (p<0.001) and EQ-5D 4.00 (0.49 to 19.75); (p=0.04). There was also an improvement in cough frequency -60 (-43 to -95) coughs/24 hours (p<0.001), but no statistically significant effect on sleep disturbance was identified | ||
| 520 | |a CONCLUSIONS: Regular use of an Acapella device improves symptoms and quality of life in people with COPD who produce sputum daily or most days | ||
| 520 | |a TRIAL REGISTRATION NUMBER: ISRCTN44651852 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COPD Exacerbations | |
| 650 | 4 | |a Cough/Mechanisms/Pharmacology | |
| 650 | 4 | |a Respiratory Muscles | |
| 700 | 1 | |a Alsulayyim, Abdullah S |e verfasserin |4 aut | |
| 700 | 1 | |a Alasmari, Ali M |e verfasserin |4 aut | |
| 700 | 1 | |a Philip, Keir E J |e verfasserin |4 aut | |
| 700 | 1 | |a Buttery, Sara C |e verfasserin |4 aut | |
| 700 | 1 | |a Banya, Winston A S |e verfasserin |4 aut | |
| 700 | 1 | |a Polkey, Michael I |e verfasserin |4 aut | |
| 700 | 1 | |a Birring, Surinder S |e verfasserin |4 aut | |
| 700 | 1 | |a Hopkinson, Nicholas S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thorax |d 1946 |g 78(2023), 2 vom: 24. Feb., Seite 136-143 |w (DE-627)NLM00010387X |x 1468-3296 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:2 |g day:24 |g month:02 |g pages:136-143 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/thorax-2022-219077 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 2 |b 24 |c 02 |h 136-143 | ||